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T he chronic kidney disease (CKD) population has grown exponentially over the past decade and is projected to grow consistently in the next decade due to an increase in the incidence of obesity and diabetes and a decrease in mortality rates (1) . Cardiovascular disease is the leading cause of morbidity and mortality in patients with CKD (1, 2) . However, there is a "treatment risk paradox," in that these high-risk patients have lower rates of medical therapy, referral for stress testing, cardiac catheterization, and revascularization compared with low-risk patients (2) . Moreover, the majority of cardiovascular clinical trials routinely exclude this high-risk group of patients (3) . The evidence-based management of these patients, therefore, relies on extrapolating the results from clinical trials in non-CKD cohorts and applying them to patients with CKD. However, it is not known whether this extrapolation is accurate.
In patients with obstructive coronary artery dis- The inclusion criteria were the following: 1) patients with CKD, defined as those with an estimated glomerular filtration rate (eGFR) ( STATISTICAL ANALYSIS. Propensity-score matching.
To adjust for differences in measured baseline characteristics between the PCI and CABG groups and to assemble a cohort of patients with similar baseline characteristics, propensity-score matching was used. The propensity score is a conditional probability of having a particular exposure (EES vs. CABG), given a set of baseline-measured covariates (7, 8) . A nonparsimonious multivariable logistic regression model (9) , using EES use as the dependent variable and all of the baseline characteristics outlined in Table 1 as covariates, was used to estimate the propensity scores. Matching was performed using a 1:1 matching protocol without replacement (Greedy matching algorithm), using a caliper width equal to 0.2 of the SD of the logit of the propensity score. Absolute standardized differences were estimated for all baseline covariates before and after matching to assess pre-match and post-match imbalances (10) . Absolute standardized differences <10% for a given covariate indicate a relatively small imbalance (10) . The risks of outcomes were analyzed in the matched cohort using a Cox proportional regression model after stratifying the matched pairs.
S u b g r o u p a n a l y s e s . Pre-specified subgroup analyses were performed on the basis of anatomy: 
RESULTS
We identified 11,305 patients with CKD and multivessel disease who fulfilled the entry criteria ( Table 2) . Table 2 ). This was consistent across anatomic subgroups on the basis of the number of diseased vessels and completeness of revascularization (p interaction >0.05) ( Table 3 ). In addition, in the cohort not on dialysis, subgroup analysis on the basis of eGFR categories yielded largely similar results (p interaction >0.05) ( Table 4) . Figure 3, Table 2 ).
In addition, in the cohort not on dialysis, subgroup analysis on the basis of eGFR categories yielded largely similar results ( Table 4) . Table 3 ). In addition, in the cohort not on dialysis, subgroup analysis on the basis of eGFR categories yielded largely similar results ( (Table 5) .
DISCUSSION
The results of this study of 5,920 subjects with CKD and multivessel disease showed that PCI using the latestgeneration stents (EES) was associated with lower short-term risk (death, stroke, and repeat revascularization), similar long-term risk of death, a higher risk of MI (in those with incomplete revascularization), and a lower risk of stroke, but a higher risk of repeat revascularization compared with CABG (Central Illustration). However, in the subgroup on dialysis, Bangalore et al. 
REVASCULARIZATION IN PATIENTS WITH CKD.
Patients with CKD are at high risk of cardiovascular disease and have an increased risk of death from CAD.
Although the major concern in patients with CAD and CKD is to prevent/avoid acute kidney injury (during PCI or CABG), CKD patients are 5 to 10 times more likely to die (mainly of cardiovascular causes) than experience the development of end-stage renal disease requiring dialysis (10, 11) . In a longitudinal follow-up of a large managed-care organization, Keith et al. (11) reported that the rate of end-stage renal disease was only 1.3%, whereas patients were more likely to die, with a mortality rate of 24.3%.
CAD in CKD patients tends to present with unique challenges, including earlier onset, more rapid progression, and stronger association with calcification Abbreviations as in Tables 1 and 2 .
Bangalore et al. Abbreviations as in Tables 1 and 2 . In the propensity score-matched cohort of patients, there was a higher risk of MI in the cohort who underwent percutaneous coronary intervention with EES compared with those who underwent CABG. In the subgroup of patients who underwent complete revascularization with percutaneous coronary intervention, the increased risk of MI was no longer statistically significant (hazard ratio: 1.18; 95% confidence interval: 0.67 to 2.09).
S E P T E M B E R
MI ¼ myocardial infarction; other abbreviations as in Figure 1 .
The results of this study with data from 5,920 propensity score-matched patients therefore offer important insights into the outcomes of patients who underwent PCI with the latest-generation DES (EES) or CABG. For the overall CKD cohort, PCI using EES was associated with lower short-term risk (death, stroke, and repeat revascularization) compared with CABG, consistent with the results of previous studies.
In addition, the primary outcome of death in the longer term was also not statistically different between PCI and CABG. PCI was associated with a higher risk of MI (in those with incomplete revascularization) and repeat revascularization compared with CABG. The higher risk of MI in those with incomplete revascularization with PCI is an important outcome because patients on dialysis who present with an MI have high mortality from a cardiac cause and poor long-term survival (33) . In a recent analysis of 1,786 propensity score-matched patients with CKD from Ontario, Canada, CABG was associated with improved survival compared with PCI using DES (34).
However, the study did not report outcomes with second-generation DES. Our study has 3. Abbreviations as in Tables 1 and 2 . In 5,920 patients with CKD and multivessel disease, CABG was associated with higher upfront risk of death and stroke, whereas PCI with the latest-generation drug-eluting stent (everolimus-eluting stent) was associated with an increased risk of repeat revascularization and MI (in those with incomplete revascularization).
CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular filtration rate; LT ¼ longer term; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; ST ¼ short term (30 days).
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